{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T22:18:17Z","timestamp":1778537897310,"version":"3.51.4"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100019018","name":"Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100019018","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007937","name":"Peking University","doi-asserted-by":"publisher","award":["RDL2023-08"],"award-info":[{"award-number":["RDL2023-08"]}],"id":[{"id":"10.13039\/501100007937","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009592","name":"Beijing Municipal Science and Technology Commission, Adminitrative Commission of Zhongguancun Science Park","doi-asserted-by":"publisher","award":["Z221100007422008"],"award-info":[{"award-number":["Z221100007422008"]}],"id":[{"id":"10.13039\/501100009592","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2021YFC2500300"],"award-info":[{"award-number":["2021YFC2500300"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.canlet.2025.217547","type":"journal-article","created":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T16:06:05Z","timestamp":1739549165000},"page":"217547","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["The expression level of EVI1 and clinical features help to distinguish prognostic heterogeneity in the AML entity with EVI1 overexpression"],"prefix":"10.1016","volume":"615","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-1587-6142","authenticated-orcid":false,"given":"Xiao-Hang","family":"Ma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng-Ge","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rong-Qi","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1548-0946","authenticated-orcid":false,"given":"Ya-Zhen","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Bing","family":"Duan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-Jun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-Su","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2025.217547_bib1","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1111\/bjh.13898","article-title":"Review: aberrant EVI1 expression in acute myeloid leukaemia","volume":"172","author":"Hinai","year":"2016","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.canlet.2025.217547_bib2","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/s41408-021-00457-9","article-title":"EVI1 dysregulation: impact on biology and therapy of myeloid malignancies","volume":"11","author":"Birdwell","year":"2021","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.canlet.2025.217547_bib3","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes","volume":"114","author":"Vardiman","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2025.217547_bib4","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1038\/bmt.2016.71","article-title":"Predictive value of high EVI1 expression in AML patients undergoing myeloablative allogeneic hematopoietic stem cell transplantation in first CR","volume":"51","author":"He","year":"2016","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.canlet.2025.217547_bib5","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1200\/JCO.2009.26.0646","article-title":"High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities","volume":"28","author":"Gr\u00f6schel","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2025.217547_bib6","doi-asserted-by":"crossref","DOI":"10.20452\/pamw.16300","article-title":"Molecular cytogenetics in acute myeloid leukemia in adult patients: practical implications","author":"Mr\u00f3zek","year":"2022","journal-title":"Pol. Arch. Intern. Med."},{"key":"10.1016\/j.canlet.2025.217547_bib7","series-title":"Acute Myeloid Leukemia","article-title":"Atypical 3q26\/MECOM rearrangements genocopy inv(3)\/t(3;3","author":"Ottema","year":"2020"},{"key":"10.1016\/j.canlet.2025.217547_bib8","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2025.217547_bib9","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2025.217547_bib10","doi-asserted-by":"crossref","first-page":"503","DOI":"10.6004\/jnccn.2023.0025","article-title":"Acute myeloid leukemia, version 3.2023, NCCN clinical practice guidelines in oncology","volume":"21","author":"Pollyea","year":"2023","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"10.1016\/j.canlet.2025.217547_bib11","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.712747","article-title":"High EVI1 expression predicts adverse outcomes in children with de novo acute myeloid leukemia","volume":"11","author":"Zheng","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.canlet.2025.217547_bib12","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1182\/blood-2002-05-1459","article-title":"High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients","volume":"101","author":"Barjesteh van Waalwijk van Doorn-Khosrovani","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2025.217547_bib13","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1200\/JCO.2009.26.0646","article-title":"High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities","volume":"28","author":"Gr\u00f6schel","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2025.217547_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.712747","article-title":"High EVI1 expression predicts adverse outcomes in children with de novo acute myeloid leukemia","volume":"11","author":"Zheng","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.canlet.2025.217547_bib15","doi-asserted-by":"crossref","first-page":"4329","DOI":"10.1182\/blood-2007-10-119230","article-title":"High EVI1 levels predict adverse outcome in acute myeloid leukemia: prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated","volume":"111","author":"Lugthart","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2025.217547_bib16","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1007\/s10238-022-00913-1","article-title":"Cytogenetics analysis as the central point of genetic testing in acute myeloid leukemia (AML): a laboratory perspective for clinical applications","volume":"23","author":"Rosli","year":"2023","journal-title":"Clin. Exp. Med."},{"key":"10.1016\/j.canlet.2025.217547_bib17","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.mne.2018.10.006","article-title":"Fluorescence in situ hybridization (FISH): history, limitations and what to expect from micro-scale FISH?","volume":"1","author":"Huber","year":"2018","journal-title":"Micro Nano Eng."},{"key":"10.1016\/j.canlet.2025.217547_bib18","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/2050-7771-2-3","article-title":"Fluorescence in situ hybridization (FISH): an increasingly demanded tool for biomarker research and personalized medicine","volume":"2","author":"Hu","year":"2014","journal-title":"Biomark. Res."},{"key":"10.1016\/j.canlet.2025.217547_bib19","doi-asserted-by":"crossref","first-page":"e959","DOI":"10.1097\/HS9.0000000000000959","article-title":"EVI1-mediated programming of normal and malignant hematopoiesis","volume":"7","author":"Lux","year":"2023","journal-title":"Hemasphere"},{"key":"10.1016\/j.canlet.2025.217547_bib20","doi-asserted-by":"crossref","first-page":"758","DOI":"10.12659\/MSM.905903","article-title":"High EVI1 expression predicts poor outcomes in adult acute myeloid leukemia patients with intermediate cytogenetic risk receiving chemotherapy","volume":"24","author":"Qin","year":"2018","journal-title":"Med. Sci. Monit."},{"key":"10.1016\/j.canlet.2025.217547_bib21","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/ijlh.13987","article-title":"The adverse impact of ecotropic viral integration site-1 (EVI1) overexpression on the prognosis of acute myeloid leukemia with KMT2A gene rearrangement in different risk stratification subtypes","volume":"45","author":"Liu","year":"2023","journal-title":"Int J Lab Hematol"},{"key":"10.1016\/j.canlet.2025.217547_bib22","doi-asserted-by":"crossref","first-page":"4056","DOI":"10.1182\/blood-2012-11-468348","article-title":"MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: results from the AML05 multicenter trial","volume":"121","author":"Zhu","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2025.217547_bib23","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1080\/10428194.2017.1352091","article-title":"The initial level of MLL -partial tandem duplication affects the clinical outcomes in patients with acute myeloid leukemia","volume":"59","author":"Kong","year":"2018","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.canlet.2025.217547_bib24","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1007\/s00277-023-05324-0","article-title":"Comparison of outcomes for patients with acute myeloid leukemia undergoing haploidentical stem cell transplantation in first and second complete remission","volume":"102","author":"Yu","year":"2023","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.canlet.2025.217547_bib25","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s00277-008-0591-8","article-title":"Nucleophosmin mutations in Chinese adults with acute myelogenous leukemia","volume":"88","author":"Ruan","year":"2009","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.canlet.2025.217547_bib26","doi-asserted-by":"crossref","first-page":"758","DOI":"10.12659\/MSM.905903","article-title":"High EVI1 expression predicts poor outcomes in adult acute myeloid leukemia patients with intermediate cytogenetic risk receiving chemotherapy","volume":"24","author":"Qin","year":"2018","journal-title":"Med. Sci. Monit."},{"key":"10.1016\/j.canlet.2025.217547_bib27","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s10238-024-01297-0","article-title":"TET2 mutations contribute to adverse prognosis in acute myeloid leukemia (AML): results from a comprehensive analysis of 502 AML cases and the Beat AML public database","volume":"24","author":"Pan","year":"2024","journal-title":"Clin. Exp. Med."},{"key":"10.1016\/j.canlet.2025.217547_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.217427","article-title":"Driver mutation landscape of acute myeloid leukemia provides insights for neoantigen-based immunotherapy","volume":"611","author":"Jin","year":"2025","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2025.217547_bib29","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1182\/blood.2021014604","article-title":"An LSC-based MRD assay to complement the traditional MFC method for prediction of AML relapse: a prospective study","volume":"140","author":"Li","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2025.217547_bib30","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1080\/10428194.2017.1352091","article-title":"The initial level of MLL-partial tandem duplication affects the clinical outcomes in patients with acute myeloid leukemia","volume":"59","author":"Kong","year":"2018","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.canlet.2025.217547_bib31","doi-asserted-by":"crossref","first-page":"e959","DOI":"10.1097\/HS9.0000000000000959","article-title":"EVI1-mediated programming of normal and malignant hematopoiesis","volume":"7","author":"Lux","year":"2023","journal-title":"Hemasphere"},{"key":"10.1016\/j.canlet.2025.217547_bib32","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1182\/blood-2015-05-646489","article-title":"Clinical and prognostic significance of 3q26.2 and other chromosome 3 abnormalities in CML in the era of tyrosine kinase inhibitors","volume":"126","author":"Wang","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2025.217547_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216518","article-title":"Unveiling autophagy complexity in leukemia: the molecular landscape and possible interactions with apoptosis and ferroptosis","volume":"582","author":"Jung","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2025.217547_bib34","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1111\/bjh.12444","article-title":"High EVI1 expression is associated with MLL rearrangements and predicts decreased survival in paediatric acute myeloid leukaemia: a report from the children's oncology group","volume":"162","author":"Ho","year":"2013","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.canlet.2025.217547_bib35","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/s41409-020-01048-1","article-title":"The role of EVI1 gene quantification in AML patients with 11q23\/MLL rearrangement after allogeneic hematopoietic stem cell transplantation","volume":"56","author":"Jiang","year":"2021","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.canlet.2025.217547_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.217290","article-title":"Inhibition of TGF-\u03b2 signaling in bone marrow endothelial cells promotes hematopoietic recovery in acute myeloid leukemia patients","volume":"605","author":"Wang","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2025.217547_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2022.215579","article-title":"Functional genomic approaches in acute myeloid leukemia: insights into disease models and the therapeutic potential of reprogramming","volume":"533","author":"Patel","year":"2022","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2025.217547_bib38","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.3324\/haematol.2019.225953","article-title":"EVI1 triggers metabolic reprogramming associated with leukemogenesis and increases sensitivity to L-asparaginase","volume":"105","author":"Saito","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.canlet.2025.217547_bib39","doi-asserted-by":"crossref","first-page":"5838","DOI":"10.1182\/blood-2011-11-393827","article-title":"EVI1 is critical for the pathogenesis of a subset of MLL-AF9\u2013rearranged AMLs","volume":"119","author":"Bindels","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2025.217547_bib40","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1080\/15384101.2019.1618642","article-title":"Hematopoietic transformation in the absence of MLL1\/KMT2A: distinctions in target gene reactivation","volume":"18","author":"Chen","year":"2019","journal-title":"Cell Cycle"},{"key":"10.1016\/j.canlet.2025.217547_bib41","doi-asserted-by":"crossref","first-page":"5838","DOI":"10.1182\/blood-2011-11-393827","article-title":"EVI1 is critical for the pathogenesis of a subset of MLL-AF9\u2013rearranged AMLs","volume":"119","author":"Bindels","year":"2012","journal-title":"Blood"}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383525001119?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383525001119?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T22:05:49Z","timestamp":1778537149000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383525001119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":41,"alternative-id":["S0304383525001119"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2025.217547","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The expression level of EVI1 and clinical features help to distinguish prognostic heterogeneity in the AML entity with EVI1 overexpression","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2025.217547","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"217547"}}